Review



periplocin  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress periplocin
    Periplocin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n1381/Periplocin/10__1016_slash_j__joim__2026__07__002-64-0-5
    Average 94 stars, based on 9 article reviews
    periplocin - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Concentration Assay:

    Article Title: Periplocin targets LRP4 to regulate metabolic homeostasis and anti-inflammation for the treatment of IVDD.
    Article Snippet: Background: Intervertebral disc degeneration (IVDD) is characterized by deteriorating intervertebral discs, leading primarily to low back pain and leg pain.. Most current treatments for IVDD primarily address symptoms without targeting the underlying degenerative process.. Moreover, tumor necrosis factor-α (TNF-α)-mediated inflammation and degradation of the nucleus pulposus (NP) extracellular matrix (ECM) influence this pathological process.

    Liquid Chromatography with Mass Spectroscopy:

    Article Title: Periplocin targets LRP4 to regulate metabolic homeostasis and anti-inflammation for the treatment of IVDD.
    Article Snippet: Background: Intervertebral disc degeneration (IVDD) is characterized by deteriorating intervertebral discs, leading primarily to low back pain and leg pain.. Most current treatments for IVDD primarily address symptoms without targeting the underlying degenerative process.. Moreover, tumor necrosis factor-α (TNF-α)-mediated inflammation and degradation of the nucleus pulposus (NP) extracellular matrix (ECM) influence this pathological process.

    Control:

    Article Title: Periplocin targets LRP4 to regulate metabolic homeostasis and anti-inflammation for the treatment of IVDD.
    Article Snippet: Background: Intervertebral disc degeneration (IVDD) is characterized by deteriorating intervertebral discs, leading primarily to low back pain and leg pain.. Most current treatments for IVDD primarily address symptoms without targeting the underlying degenerative process.. Moreover, tumor necrosis factor-α (TNF-α)-mediated inflammation and degradation of the nucleus pulposus (NP) extracellular matrix (ECM) influence this pathological process.

    CCK-8 Assay:

    Article Title: Periplocin Has Anti-Tumor Actions In Prostate Cancer Through Modulating The MiR-3614-5p/SLC4A4 Axis
    Article Snippet: Periplocin (PPLN) can inhibit malignant tumors including prostate cancer (PC), but its impact on prostate cancer is unknown.. Prostate cancer cells were treated with various doses of periplocin (PPLN), and the optimal treatment concentration of PPLN was determined using a CCK-8 assay.. Bioinformatics analysis was performed to examine the link between miR-3614-5p and SLC4A4.

    Solvent:

    Article Title: C-Src/β-DG-mediated impairment of glia-vascular unit integrity via AQP4 depolarization contributes to secondary hydrocephalus after intraventricular hemorrhage
    Article Snippet: .. The rats were randomly divided into the following four groups, as shown in Figure S1 and Table S1: Sham (sham operation), IVH (IVH followed by administration of a drug solvent), IVH+PP2 groups (IVH followed by administration of the c-Src inhibitor PP2, HY-13805, MedChemExpress, USA), and IVH+Periplocin (IVH followed by administration of the c-Src activator Periplocin, HY-N1381, MedChemExpress, USA). ..



    Similar Products

    periplocin  (MedChemExpress)
    94
    MedChemExpress periplocin
    Periplocin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n1381/Periplocin/10__1016_slash_j__joim__2026__07__002-64-0-5
    Average 94 stars, based on 1 article reviews
    periplocin - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    ivh periplocin  (MedChemExpress)
    94
    MedChemExpress ivh periplocin
    Ivh Periplocin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n1381/Periplocin/10__1097_slash_js9__0000000000003867-64-45-56
    Average 94 stars, based on 1 article reviews
    ivh periplocin - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    concentration periplocin  (MedChemExpress)
    94
    MedChemExpress concentration periplocin
    Concentration Periplocin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n1381/Periplocin/pm40440911-45-14-19
    Average 94 stars, based on 1 article reviews
    concentration periplocin - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    ppln  (MedChemExpress)
    94
    MedChemExpress ppln
    <t>PPLN</t> enhances the sensitivity <t>of</t> <t>HepG2/OXA</t> cells to OXA. (A) The impact of various doses of PPLN on the viability of HepG2/OXA cells was evaluated using the CCK-8 assay; (B) The IC50 of HepG2/OXA cells against OXA in the presence or absence of PPLN (80 nM) was assessed using the CCK-8 assay; (C) The combination index was calculated based on the inhibition rate of cell viability by PPLN and OXA to determine whether the combination therapy of OXA and PPLN is synergistic; (D and F) The proliferation of HepG2/OXA cells treated with OXA (10 µM), PPLN (80 nM), or OXA+PPLN was detected using EDU staining; (E and G) Colony formation assay was used to examine the influence of OXA (10 µM), PPLN (80 nM), or OXA+PPLN combination treatment on colony formation in HepG2/OXA cells; (H and I) The apoptosis rate of HepG2/OXA cells after OXA (10 µM), PPLN (80 nM), or OXA+PPLN co-treatment was quantified using flow cytometry; (J and K) Western blot analysis was used to examine the levels of Bax and Caspase 3 in HepG2/OXA cells following treatment with OXA (10 µM), PPLN (80 nM), or OXA+PPLN. PPLN: Periplocin; HCC: Hepatocellular carcinoma; HepG2/OXA: OXA-resistant HepG2 cell line; OXA: Oxaliplatin.
    Ppln, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n1381/Periplocin/pmc11959402-50-27-36
    Average 94 stars, based on 1 article reviews
    ppln - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    PPLN enhances the sensitivity of HepG2/OXA cells to OXA. (A) The impact of various doses of PPLN on the viability of HepG2/OXA cells was evaluated using the CCK-8 assay; (B) The IC50 of HepG2/OXA cells against OXA in the presence or absence of PPLN (80 nM) was assessed using the CCK-8 assay; (C) The combination index was calculated based on the inhibition rate of cell viability by PPLN and OXA to determine whether the combination therapy of OXA and PPLN is synergistic; (D and F) The proliferation of HepG2/OXA cells treated with OXA (10 µM), PPLN (80 nM), or OXA+PPLN was detected using EDU staining; (E and G) Colony formation assay was used to examine the influence of OXA (10 µM), PPLN (80 nM), or OXA+PPLN combination treatment on colony formation in HepG2/OXA cells; (H and I) The apoptosis rate of HepG2/OXA cells after OXA (10 µM), PPLN (80 nM), or OXA+PPLN co-treatment was quantified using flow cytometry; (J and K) Western blot analysis was used to examine the levels of Bax and Caspase 3 in HepG2/OXA cells following treatment with OXA (10 µM), PPLN (80 nM), or OXA+PPLN. PPLN: Periplocin; HCC: Hepatocellular carcinoma; HepG2/OXA: OXA-resistant HepG2 cell line; OXA: Oxaliplatin.

    Journal: Biomolecules and Biomedicine

    Article Title: Periplocin improves the sensitivity of oxaliplatin-resistant hepatocellular carcinoma cells by inhibiting M2 macrophage polarization

    doi: 10.17305/bb.2024.10928

    Figure Lengend Snippet: PPLN enhances the sensitivity of HepG2/OXA cells to OXA. (A) The impact of various doses of PPLN on the viability of HepG2/OXA cells was evaluated using the CCK-8 assay; (B) The IC50 of HepG2/OXA cells against OXA in the presence or absence of PPLN (80 nM) was assessed using the CCK-8 assay; (C) The combination index was calculated based on the inhibition rate of cell viability by PPLN and OXA to determine whether the combination therapy of OXA and PPLN is synergistic; (D and F) The proliferation of HepG2/OXA cells treated with OXA (10 µM), PPLN (80 nM), or OXA+PPLN was detected using EDU staining; (E and G) Colony formation assay was used to examine the influence of OXA (10 µM), PPLN (80 nM), or OXA+PPLN combination treatment on colony formation in HepG2/OXA cells; (H and I) The apoptosis rate of HepG2/OXA cells after OXA (10 µM), PPLN (80 nM), or OXA+PPLN co-treatment was quantified using flow cytometry; (J and K) Western blot analysis was used to examine the levels of Bax and Caspase 3 in HepG2/OXA cells following treatment with OXA (10 µM), PPLN (80 nM), or OXA+PPLN. PPLN: Periplocin; HCC: Hepatocellular carcinoma; HepG2/OXA: OXA-resistant HepG2 cell line; OXA: Oxaliplatin.

    Article Snippet: After attachment to the wall, the original medium was replaced with 200 μL of medium containing OXA (2.5, 5, 10, 20, 40, and 80 μM, HY-17371, MedChemExpress), PPLN (20, 40, 80, 150, and 300 nM, HY-N1381, MedChemExpress) or M2-CM (1:1 ratio with DMEM medium).

    Techniques: CCK-8 Assay, Inhibition, Staining, Colony Assay, Flow Cytometry, Western Blot

    PPLN inhibits M2 macrophage polarization. (A and B) The effect of PPLN treatment on M1 and M2 macrophage viability was detected using the CCK-8 assay; (C–F) The levels of polarization markers CD206, IL-10, Arg1, and Fizz1 in M2 macrophages were quantified using RT-qPCR; (G–J) The levels of polarization markers CD86, iNOS, IL-6, and TNF-α in M1 macrophages were examined using RT-qPCR; (K) The expression of CD206, a polarization marker in M2 macrophages, was detected by flow cytometry; (L) Expression of CD86, a marker of M1 macrophage polarization, detected by flow cytometry. PPLN: Periplocin.

    Journal: Biomolecules and Biomedicine

    Article Title: Periplocin improves the sensitivity of oxaliplatin-resistant hepatocellular carcinoma cells by inhibiting M2 macrophage polarization

    doi: 10.17305/bb.2024.10928

    Figure Lengend Snippet: PPLN inhibits M2 macrophage polarization. (A and B) The effect of PPLN treatment on M1 and M2 macrophage viability was detected using the CCK-8 assay; (C–F) The levels of polarization markers CD206, IL-10, Arg1, and Fizz1 in M2 macrophages were quantified using RT-qPCR; (G–J) The levels of polarization markers CD86, iNOS, IL-6, and TNF-α in M1 macrophages were examined using RT-qPCR; (K) The expression of CD206, a polarization marker in M2 macrophages, was detected by flow cytometry; (L) Expression of CD86, a marker of M1 macrophage polarization, detected by flow cytometry. PPLN: Periplocin.

    Article Snippet: After attachment to the wall, the original medium was replaced with 200 μL of medium containing OXA (2.5, 5, 10, 20, 40, and 80 μM, HY-17371, MedChemExpress), PPLN (20, 40, 80, 150, and 300 nM, HY-N1381, MedChemExpress) or M2-CM (1:1 ratio with DMEM medium).

    Techniques: CCK-8 Assay, Quantitative RT-PCR, Expressing, Marker, Flow Cytometry

    PPLN enhances OXA sensitivity of HepG2/OXA cells by inhibiting M2 macrophage polarization. (A) CCK-8 assay was used to assess the IC50 values of OXA in HepG2/OXA cells after PPLN or PPLN+M2-CM treatment; (B and E) The proliferation of HepG2/OXA cells treated with OXA, OXA+PPLN, or OXA+PPLN+M2-CM was detected using EdU staining; (C and F) Clone formation assay was used to detect clone formation in HepG2/OXA cells after OXA, OXA+PPLN, or OXA+PPLN+M2-CM treatment; (D and G) The apoptosis rate of HepG2/OXA cells treated with OXA, OXA+PPLN, or OXA+PPLN+M2-CM was examined using flow cytometry; (H and I) The levels of Bax and Caspase 3 in HepG2/OXA cells after OXA, OXA+PPLN, or OXA+PPLN+M2-CM treatment were detected using Western blot. PPLN: Periplocin; HCC: Hepatocellular carcinoma; HepG2/OXA: OXA-resistant HepG2 cell line; OXA: Oxaliplatin; M2-CM: M2 macrophage-conditioned medium.

    Journal: Biomolecules and Biomedicine

    Article Title: Periplocin improves the sensitivity of oxaliplatin-resistant hepatocellular carcinoma cells by inhibiting M2 macrophage polarization

    doi: 10.17305/bb.2024.10928

    Figure Lengend Snippet: PPLN enhances OXA sensitivity of HepG2/OXA cells by inhibiting M2 macrophage polarization. (A) CCK-8 assay was used to assess the IC50 values of OXA in HepG2/OXA cells after PPLN or PPLN+M2-CM treatment; (B and E) The proliferation of HepG2/OXA cells treated with OXA, OXA+PPLN, or OXA+PPLN+M2-CM was detected using EdU staining; (C and F) Clone formation assay was used to detect clone formation in HepG2/OXA cells after OXA, OXA+PPLN, or OXA+PPLN+M2-CM treatment; (D and G) The apoptosis rate of HepG2/OXA cells treated with OXA, OXA+PPLN, or OXA+PPLN+M2-CM was examined using flow cytometry; (H and I) The levels of Bax and Caspase 3 in HepG2/OXA cells after OXA, OXA+PPLN, or OXA+PPLN+M2-CM treatment were detected using Western blot. PPLN: Periplocin; HCC: Hepatocellular carcinoma; HepG2/OXA: OXA-resistant HepG2 cell line; OXA: Oxaliplatin; M2-CM: M2 macrophage-conditioned medium.

    Article Snippet: After attachment to the wall, the original medium was replaced with 200 μL of medium containing OXA (2.5, 5, 10, 20, 40, and 80 μM, HY-17371, MedChemExpress), PPLN (20, 40, 80, 150, and 300 nM, HY-N1381, MedChemExpress) or M2-CM (1:1 ratio with DMEM medium).

    Techniques: CCK-8 Assay, Staining, Tube Formation Assay, Flow Cytometry, Western Blot

    PPLN enhances OXA sensitivity in HepG2/OXA cells in vivo . (A) The process of constructing the nude mouse subcutaneous graft tumor model; (B) The effect on tumor growth after subcutaneous injection of OXA (10 mg/kg), PPLN (15 mg/kg), or OXA+PPLN compared to the control group ( n ═ 5, day 28); (C) Measurement of subcutaneous grafted tumor volumes in nude mice at 7, 14, 21, and 28 days after different treatments; (D) Measurement of tumor weights in nude mice after different treatments (day 28); (E) Tunel staining was used to examine apoptosis in tumor tissues of nude mice; (F–J) The levels of M2 macrophage markers (CD206 and Arg1) and M1 macrophage markers (CD86 and iNOS) in tumor tissues were assessed using immunohistochemistry; (K–M) Immunofluorescence detected the expression of the M2 macrophage marker CD206 and the M1 macrophage marker CD86 in tumor tissues. PPLN: Periplocin; HepG2/OXA: OXA-resistant HepG2 cell line; OXA: Oxaliplatin; Arg1: Arginase-1; iNOS: Inducible nitric oxide synthase.

    Journal: Biomolecules and Biomedicine

    Article Title: Periplocin improves the sensitivity of oxaliplatin-resistant hepatocellular carcinoma cells by inhibiting M2 macrophage polarization

    doi: 10.17305/bb.2024.10928

    Figure Lengend Snippet: PPLN enhances OXA sensitivity in HepG2/OXA cells in vivo . (A) The process of constructing the nude mouse subcutaneous graft tumor model; (B) The effect on tumor growth after subcutaneous injection of OXA (10 mg/kg), PPLN (15 mg/kg), or OXA+PPLN compared to the control group ( n ═ 5, day 28); (C) Measurement of subcutaneous grafted tumor volumes in nude mice at 7, 14, 21, and 28 days after different treatments; (D) Measurement of tumor weights in nude mice after different treatments (day 28); (E) Tunel staining was used to examine apoptosis in tumor tissues of nude mice; (F–J) The levels of M2 macrophage markers (CD206 and Arg1) and M1 macrophage markers (CD86 and iNOS) in tumor tissues were assessed using immunohistochemistry; (K–M) Immunofluorescence detected the expression of the M2 macrophage marker CD206 and the M1 macrophage marker CD86 in tumor tissues. PPLN: Periplocin; HepG2/OXA: OXA-resistant HepG2 cell line; OXA: Oxaliplatin; Arg1: Arginase-1; iNOS: Inducible nitric oxide synthase.

    Article Snippet: After attachment to the wall, the original medium was replaced with 200 μL of medium containing OXA (2.5, 5, 10, 20, 40, and 80 μM, HY-17371, MedChemExpress), PPLN (20, 40, 80, 150, and 300 nM, HY-N1381, MedChemExpress) or M2-CM (1:1 ratio with DMEM medium).

    Techniques: In Vivo, Injection, Control, TUNEL Assay, Staining, Immunohistochemistry, Immunofluorescence, Expressing, Marker